Digital IndustryHealth technologies

Stem Cell NanoImaging – Advances and Applications Conference

Stem Cell NanoImaging – Advances and Applications Conference

nTRACK Open Day Workshop 2022

Announcement

Location: ONLINE 

Date: 14th March 2022

Registration: http://stemcellnanoimaging-register.com/

Agenda: Coming Soon

The nTRACK Project is organising a conference  on Stem Cell NanoImaging – Advances and Applications on the 14th March 2022, as an online event. This would be a great opportunity to learn about the results of the project, meet the project partners and learn about technologies they have developed related to nanomaterials in biomedical applications. We are also using this opportunity to invite guests and speakers that are not directly involved in the project, but interested in commercialisation of technologies being develop.

The nTRACK is a 4-year EU Horizon 2020 project that started in October 2017 (www.n-track.eu) that aims to develop a safe and highly sensitive multimodal nano imaging agent enabling non-invasive, quantitative and longitudinal stem cell tracking and whole-body bio distribution. nTRACK will also provide information on cell (long-term) viability using the combination of CT, MRI and PET, which are imaging modalities that are clinically available. The synthesis of nTRACK NPs and cellular labelling processes will be scaled up and will follow good manufacturing practice (GMP) requirements. A second goal is to establish a predictive model for early assessment of treatment effectiveness, based on short-term evaluation of the typical migration and bio distribution patterns of the stem cells. This predictive model could substantially improve overall management of the disease and will transform cell therapy treatment from “one size fits all’ concept towards personalised treatment.

The nTRACK Project Partners are LEITAT, Asphalion, BIOEMTECH, Cambridge Nanomaterials Technology Ltd, MyBiotech, RIVM, Unimedizin Mainz (UMC), Vivotecnia Research S.L, Vall d’Hebron Research Institute (VHIR), Bar Ilan University and Pluristem Therapeutics.